Skip to main content
Home / Current Medicinal Chemistry, Volume 19, Number 13
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Publisher: Bentham Science Publishers

More about this publication?
Volume 19, Number 13, 2012

Articles

Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
pp. 1899-1920(22)
Authors: Szalardy, L.; Klivenyi, P.; Zadori, D.; Fulop, F.; Toldi, J.; Vecsei, L.

Favourites:
ADD

Privileged Structures - Dream or Reality: Preferential Organization of Azanaphthalene Scaffold
pp. 1921-1945(25)
Authors: Polanski, J.; Kurczyk, A.; Bak, A.; Musiol, R.

Favourites:
ADD

Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
pp. 1946-2025(80)
Authors: Palmeira, A.; Sousa, E.; H. Vasconcelos, M.; M. Pinto, M.

Favourites:
ADD

Recent Advances in the Research of 2,3-Diaryl-1,3-thiazolidin-4-one Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors
pp. 2026-2037(12)
Authors: Tian, Ye; Zhan, Peng; Rai, Diwakar; Zhang, Jiyan; De Clercq, Erik; Liu, Xinyong

Favourites:
ADD

UDP-3-O-(R-3-hydroxymyristoyl)-N-Acetylglucosamine Deacetylase (LpxC) Inhibitors: A New Class of Antibacterial Agents
pp. 2038-2050(13)
Authors: Zhang, J.; Zhang, L.; Li, X.; Xu, W.

Favourites:
ADD

Activity of Epiisopiloturine Against Schistosoma mansoni
pp. 2051-2058(8)
Authors: M. Veras, L.; A. Guimaraes, M.; D. Campelo, Y.; M. Vieira, M.; Nascimento, C.; F. Lima, D.; Vasconcelos, L.; Nakano, E.; S. Kuckelhaus, S.; C. Batista, M.; R. Leite, J.; Moraes, J.

Favourites:
ADD

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content